STAT3 and small cell lung carcinoma: Besides CXCR4 antagonists that are currently investigated in an in vivo model for SCLC, STAT3 inhibitors on its own or in combination with CXCR4 inhibitors will be very interesting to consider as therapeutic option for the treatment of patients with SCLC.